Advertisement

Short-term effects of two continuous combined oestrogen–progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: A randomised controlled trial

  • Alyde T. de Kraker
    Affiliations
    Project ‘Ageing Women’ and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands

    Department of Obstetrics & Gynaecology, VU University Medical Center, Amsterdam, The Netherlands
    Search for articles by this author
  • Peter Kenemans
    Affiliations
    Project ‘Ageing Women’ and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands

    Department of Obstetrics & Gynaecology, VU University Medical Center, Amsterdam, The Netherlands
    Search for articles by this author
  • Raimond G.V. Smolders
    Affiliations
    Project ‘Ageing Women’ and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands

    Department of Obstetrics & Gynaecology, VU University Medical Center, Amsterdam, The Netherlands
    Search for articles by this author
  • Maurice V.A.M. Kroeks
    Affiliations
    Project ‘Ageing Women’ and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands

    Department of Obstetrics & Gynaecology, Diakonessenhuis Utrecht, The Netherlands
    Search for articles by this author
  • Marius J. van der Mooren
    Correspondence
    Corresponding author at: Department of Obstetrics & Gynaecology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Tel.: +31 20 4443244; fax: +31 20 4444422.
    Affiliations
    Project ‘Ageing Women’ and the Institute for Cardiovascular Research-Vrije Universiteit (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands

    Department of Obstetrics & Gynaecology, VU University Medical Center, Amsterdam, The Netherlands
    Search for articles by this author
Published:November 12, 2008DOI:https://doi.org/10.1016/j.ejogrb.2008.10.007

      Abstract

      Objective

      To compare the short-term effects of two oral continuous combined oestrogen–progestogen treatment regimens on blood concentrations of several cardiovascular risk markers in healthy postmenopausal women.

      Study design

      In a 12-week randomised controlled study, 48 healthy non-hysterectomised postmenopausal women, aged 41–58 years, received either no treatment (control group; n = 16), or daily oral continuous combined treatment with 1 mg micronised 17β-oestradiol plus 5 mg dydrogesterone (E/D group; n = 18) or 0.625 mg conjugated equine oestrogens plus 5 mg medroxyprogesterone acetate (CEE/MPA group; n = 14).
      Fasting blood sampling was performed at baseline and after 12 weeks of follow-up.

      Results

      Compared with the control group, 12-week treatment with E/D or CEE/MPA reduced fibrinogen (−7.7%, p = 0.004 and −3.3%, p = 0.083, respectively), factor VII-act (−8.7%, p = 0.14 and −9.7%, p = 0.06, respectively), homocysteine (−20.5%, p = 0.02 and −26.7%, p = 0.005, respectively), and IGF-1 (−27.9%, p < 0.001 and −18.1%, p = 0.002, respectively), but increased factor VII-ag (+10.1%, p = 0.03 and +4.4%, p = 0.46, respectively), endothelin-1 (+15.2%, p = 0.12 and +20.0%, p = 0.13, respectively) and C-reactive protein (+88.8%, p = 0.18 and +71.0%, p = 0.44, respectively). Fibrinolytic factors were not affected by either hormone therapy (HT).

      Conclusions

      Short-term oral continuous combined therapy with oestradiol/dydrogesterone and conjugated equine oestrogens/medroxyprogesterone acetate had comparable effects on the investigated cardiovascular risk markers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Grodstein F.
        • Stampfer M.J.
        • Manson J.E.
        • Colditz G.A.
        • Willett W.C.
        • Rosner B.
        • Speizer F.E.
        • Hennekens C.H.
        Postmenopausal hormone therapy and mortality.
        N Engl J Med. 1997; 336: 1769-1775
        • Hulley S.
        • Grady D.
        • Bush T.
        • Furberg C.
        • Herrington D.
        • Riggs B.
        • Vittinghoff E.
        Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
        JAMA. 1998; 280: 605-613
        • Manson J.E.
        • Hsia J.
        • Johnson K.C.
        • et al.
        Estrogen plus progestin and the risk of coronary heart disease.
        N Engl J Med. 2003; 349: 523-534
        • Anderson G.L.
        • Limacher M.
        • Assaf A.R.
        • et al.
        Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial.
        JAMA. 2004; 291: 1701-1712
        • Van Baal W.M.
        • Kenemans P.
        • van der Mooren M.J.
        • Kessel H.
        • Emeis J.J.
        • Stehouwer C.D.
        Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women.
        Thromb Haemost. 1999; 81: 925-928
        • Van Baal W.M.
        • Emeis J.J.
        • van der Mooren M.J.
        • Kessel H.
        • Kenemans P.
        • Stehouwer C.D.
        Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
        Thromb Haemost. 2000; 83: 29-34
        • Godsland I.F.
        Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000.
        Fertil Steril. 2001; 75: 898-915
        • Gelfand M.M.
        • Fugere P.
        • Bissonnette B.
        Cardiovascular risk factors during sequentially combined 17β oestradiol and dydrogesterone (Femoston®); results from a one-year study in postmenopausal women.
        Maturitas. 1997; 26: 125-132
        • Mijatovic V.
        • Kenemans P.
        • van Baal W.M.
        • Peters-Muller E.R.A.
        • van der Mooren M.J.
        A randomised controlled study of the effects of 17β-estradiol–dydrogesterone on plasma homocysteine in postmenopausal women.
        Obstet Gynecol. 1998; 91: 432-436
        • De Kraker A.T.
        • Kenemans P.
        • Smolders R.G.
        • Kroeks M.V.
        • van der Mooren M.J.
        The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
        Maturitas. 2004; 49: 253-263
        • Claus A.
        Gerinnungsphysiologische Schnellmethode zur Bestimmung des fibrinogens.
        Acta Haemat. 1957; 17: 237-246
        • Frohlich M.
        • Schunkert H.
        • Hense H.W.
        • et al.
        Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women.
        Br J Haematol. 1998; 100: 577-581
        • Meade T.W.
        • Haines A.P.
        • Imeson J.D.
        • Stirling Y.
        • Thompson S.G.
        Menopausal status and haemostatic variables.
        Lancet. 1983; 1: 22-24
        • Van Baal W.M.
        • Kenemans P.
        • van der Mooren M.J.
        • Kooistra T.
        • Stehouwer C.D.A.
        Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women.
        Curr Med Chem. 2000; 7: 499-517
        • Hanggi W.
        • Lippuner K.
        • Riesen W.
        • Jaeger P.
        • Birkhauser M.H.
        Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.
        Br J Obstet Gynaecol. 1997; 104: 708-717
        • Ridker P.M.
        • Vaughan D.E.
        • Stampfer M.J.
        • Manson J.E.
        • Hennekens C.H.
        Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
        Lancet. 1993; 341: 1165-1168
        • Gebara O.C.E.
        • Mittleman M.A.
        • Sutherland P.
        • et al.
        Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study.
        Circulation. 1995; 91: 1952-1958
        • Scarabin P.Y.
        • Alhenc-Gelas M.
        • Plu-Bureau G.
        • Taisne P.
        • Agher R.
        • Aiach M.
        Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
        Arterioscler Thromb Vasc Biol. 1997; 17: 3071-3078
        • Ridker P.M.
        • Hennekens C.H.
        • Buring J.E.
        • Rifai N.
        C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
        N Engl J Med. 2000; 342: 836-843
        • Davison S.
        • Davis S.
        New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy.
        J Clin Endocrinol Metab. 2003; 88: 2470-2478
        • Stork S.
        • von Schacky C.
        • Angerer P.
        The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial.
        Atherosclerosis. 2002; 165: 301-307
        • Post M.S.
        • van der Mooren M.J.
        • Stehouwer C.D.A.
        • et al.
        Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial.
        Thromb Haemost. 2002; 88: 605-610
        • Ridker P.M.
        • Manson J.E.
        • Buring J.E.
        • Shih J.
        • Matias M.
        • Hennekens C.H.
        Homocysteine and risk of cardiovascular disease among postmenopausal women.
        JAMA. 1999; 281: 1817-1821
        • Hak A.E.
        • Polderman K.H.
        • Westendorp I.C.
        • et al.
        Increased plasma homocysteine after menopause.
        Atherosclerosis. 2000; 149: 163-168
        • Omland O.
        • Terje R.
        • Aakvaag A.
        • Aarsland T.
        • Dickstein K.
        Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction.
        Circulation. 1994; 89: 1573-1579
        • Ylikorkala O.
        • Orpana A.
        • Puolakka J.
        • Pyorala T.
        • Viinikka L.
        Postmenopausal hormonal replacement decreases plasma levels of endothelin-1.
        J Clin Endocrinol Metab. 1995; 80: 3384-3387
        • Hankinson S.E.
        • Willett W.C.
        • Colditz G.A.
        • et al.
        Circulating concentrations of insulin-like growth factor and risk of breast cancer.
        Lancet. 1998; 351: 1393-1396
        • Juul A.
        • Scheike T.
        • Davidsen M.
        • Gyllenborg J.
        • Jorgensen T.
        Low serum Insulin-Like Growth Factor I is associated with an increased risk of ischemic heart disease. A population-based case–control study.
        Circulation. 2002; 106: 939-944
        • Ho K.Y.
        • Evans W.S.
        • Blizzard R.M.
        • et al.
        Effects of sex and age on the 24-h profile of growth hormone secretion in man: importance of endogenous estradiol concentrations.
        J Clin Endocrinol Metab. 1987; 64: 51-58
        • Biglia N.
        • Ambroggio S.
        • Ponzone R.
        • et al.
        Modifications of serum IGF-1 IGFBPs and SHBG levels by different HRT regimens.
        Maturitas. 2003; 45: 283-291